GlassScriptPhysician profile
Kathryn Bycura
NPI 1235427238
$2,646.43
in general payments reported to CMS, 2019-2025
17 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $583 · 2022: $306 · 2023: $678 · 2024: $780 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $701.12 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $429.14 | 2021-2024 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $210.20 | 2021-2025 | Stelara, Simponi Aria, Simponi |
| Qol Medical, LLC | $208.85 | 2021-2024 | Sucraid, Sucraid |
| Celgene Corporation | $201.09 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $176.79 | 2021-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $156.46 | 2024-2025 | Voquezna |
| Medtronic, INC. | $135.11 | 2024 | Interstim |
| Takeda Pharmaceuticals U.S.A., INC. | $82.11 | 2021-2025 | Entyvio |
| Lilly USA, LLC | $74.26 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $66.18 | 2023-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $53.09 | 2021-2024 | Rebyota |
| Daiichi Sankyo INC. | $43.97 | 2022-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $36.25 | 2025 | Dupixent |
| Celltrion USA INC. | $34.70 | 2024-2025 | Vegzelma |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $23.48 | 2025 | |
| Amag Pharmaceuticals, INC. | $13.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Bycura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.